Full history for every metric is available with a Kvantra account
Aadi Bioscience, Inc. (AADI)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | $m | 14 | 1 | 15 | 24 | 26 | 7 |
| Operating profit | $m | -114 | |||||
| Net profit | $m | -3 | -110 | -61 | -66 | -64 | -21 |
| EPS reported | $ | -0.03 | |||||
| Operating cashflow per share | $ | -0.16 | |||||
| Capex per share | $ | 0.00 | |||||
| FCF per share | $ | -0.16 | |||||
| Free cash flow | $m | -98 | |||||
| Net debt | $m | -146 | |||||
| Book value equity | $m | 136 | |||||
| Book value per share | $ | 0.22 | |||||
| Number of shares | m | 618.87 | |||||
| DPS (TTM paid) | $ | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | 9.31 | |||||
| P/S LTM | x | 177.56 | |||||
| P/FCF LTM | x | -12.95 | |||||
| EV/EBITDA LTM | x | -10.76 | |||||
| EV/Sales LTM | x | 172.30 | |||||
| Earnings Yield LTM | % | -1.62% | |||||
| FCF Yield | % | -7.72% | |||||
| Quality | |||||||
| ROE | % | -15.11% | |||||
| ROIC | % | -83.93% | |||||
| Operating margin | % | -1601.1% | |||||
| Gross margin | % | 0.00% | |||||
| FCF/Sales | % | -1371.4% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | -72.50% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | - | |||||
| Net Debt/EBITDA | x | 0.33 | |||||
| EBIT/Net interest | x | 0.00 | |||||
| Net debt/market cap | % | -11.48% | |||||
| Net debt/Equity | x | -1.07 | |||||
| Gross debt/equity | x | 0.00 | |||||
Company overview
Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing highly targeted therapies for cancers defined by specific genetic alterations within the mTOR pathway. Its flagship drug candidate, FYARRO, is an investigational therapeutic composed of sirolimus conjugated with albumin. Aadi is actively evaluating FYARRO's efficacy in various malignancies that exhibit known mTOR pathway activation. This includes its application in 'tumor-agnostic' indications, where the focus is on specific genomic alterations that activate the mTOR pathway, irrespective of the tumor's origin. The company was established in 2007 and maintains its corporate headquarters in Pacific Palisades, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Aadi Bioscience, Inc. (AADI)
Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing highly targeted therapies for cancers defined by specific genetic alterations within the mTOR pathway. Its flagship drug candidate, FYARRO, is an investigational therapeutic composed of sirolimus conjugated with albumin. Aadi is actively evaluating FYARRO's efficacy in various malignancies that exhibit known mTOR pathway activation. This includes its application in 'tumor-agnostic' indications, where the focus is on specific genomic alterations that activate the mTOR pathway, irrespective of the tumor's origin. The company was established in 2007 and maintains its corporate headquarters in Pacific Palisades, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free